HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 7% in early trading. IMM2510 is expected to fill the clinical gap in the treatment of advanced lung squamous cell carcinoma.

IMMUNEONCO-B (01541) rose by over 7% in the early trading session, and as of the time of writing, it was up by 2.63%, trading at HK$3.9 with a turnover of HK$1.7963 million. In terms of news, Immuneonco announced that it recently presented the latest progress of IMM2510 in the treatment of IO refractory advanced lung squamous cell carcinoma at the ASCO 2026 conference in the form of a poster. The data showed that IMM2510 not only demonstrated significant efficacy in late-stage lung squamous cell carcinoma patients who had progressed on immunotherapy, but also exhibited excellent safety characteristics different from similar products. Based on the positive data from the Phase I study and exposure-response analysis results, a recommended Phase II dose (RP2D) of 20mg/kg Q2W has been identified, with plans for a Phase III clinical study in progress. In the article "IMMUNEONCO-B (01541) Steps into a Critical Hitting Zone with the Acceleration of Filling the Treatment Blank of Advanced Lung Squamous Cell Carcinoma and Innovation Realization," it was pointed out that with the disclosure of the significant data on IMM2510, Immuneonco's certainty in terms of differentiated original research and innovation has been further confirmed. The company is also expected to unlock more valuation potential through its pipeline of potential FIC/BIC products. Furthermore, with over HK$1 billion in cash and a differentiated innovative pipeline, Immuneonco can also return value to shareholders through stock repurchases. Currently, Immuneonco's PS valuation is only 8.69 times, indicating that the valuation level is at a bottom hitting zone. The company's intrinsic value urgently needs reevaluation in the secondary market, and investors are advised to keep a close watch.